Functional and mechanistic analyses revealed that silencing FGF17 suppressed the FGFR4/MEK5/ERK5 signaling cascade, disturbed NRF2-dependent redox homeostasis, and consequently impaired epithelial–mesenchymal transition (EMT), leading to a marked reduction in cancer cell motility and invasiveness. This evidence concerns the gene FGF17 and cancer.